Megan V. Perkins

Megan V. Perkins

Auto-generated profile, based on publicly available information

Megan V. Perkins

Department of Microbiology and Immunology (M.V.P.), University of North Carolina at Chapel Hill

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
MPMegan V. Perkins
Megan V. Perkins
SJSarah B. Joseph
Sarah B. Joseph
DDDirk P. Dittmer
Dirk P. Dittmer
NMNigel Mackman
Nigel Mackman
HIV infection has transitioned from an acute, fatal disease to a chronic one managed by antiretroviral therapy. Thus, the aging population of people living with HIV (PLWH) continues to expand. HIV infection results in a dysregulated immune system, wherein CD4 + T cells are depleted, particularly in the gastrointestinal tract, disrupting the gut epithelial barrier. Long-term HIV infection is associated with chronic inflammation through potentially direct mechanisms caused by viral replication or exposure to viral proteins and indirect mechanisms resulting from increased translocation of microbial products from the intestine or exposure to antiretroviral therapy. Chronic inflammation (as marked by IL [interleukin]-6 and CRP [C-reactive protein]) in PLWH promotes endothelial cell dysfunction and atherosclerosis. PLWH show significantly increased rates of cardiovascular disease, such as myocardial infarction (risk ratio, 1.79 [95% CI, 1.54–2.08]) and stroke (risk ratio, 2.56 [95% CI, 1.43–4.61]). In addition, PLWH have increased levels of the coagulation biomarker D-dimer and have a two to ten-fold increased risk of venous thromboembolism compared with the general population. Several small clinical trials analyzed the effect of different antithrombotic agents on platelet activation, coagulation, inflammation, and immune cell activation. Although some markers for coagulation were reduced, most agents failed to reduce inflammatory markers in PLWH. More studies are needed to understand the underlying mechanisms driving inflammation in PLWH to create better therapies for lowering chronic inflammation in PLWH. Such therapies can potentially reduce atherosclerosis, cardiovascular disease, and thrombosis rates in PLWH and thus overall mortality in this population.

2 February 2022 in Virology
Verified
Journal Article
Closed access
RMRazia Moorad
Razia Moorad
AJAngelica Juarez
Angelica Juarez
JLJustin T. Landis
Justin T. Landis
LPLinda J. Pluta
Linda J. Pluta
MPMegan Perkins
Megan Perkins
DDDirk P. Dittmer
Dirk P. Dittmer

1 February 2026 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
MPMegan V. Perkins
Megan V. Perkins
NMNigel Mackman
Nigel Mackman
Viral hemorrhagic fever (VHF) describes different diseases caused by several viruses from 6 virus families: Filoviridae , Nairoviridae , Phenuiviridae , Hepadnaviridae , Arenaviridae , and Flaviviridae . VHF was once considered a geographically localized problem, but due to expanding vector ranges and increased human contact with animal reservoirs and hosts, the number of VHF cases is increasing. As the name indicates, VHF is associated with bleeding. Both direct effects from viral infection of host cells and indirect effects caused by the host response to the virus contribute to dysregulation of the hemostatic system. Many studies have measured different parameters and various biomarkers in samples from infected humans and nonhuman primate models. For example, Ebola virus infection in a nonhuman primate model leads to increased TF (tissue factor) expression in peripheral blood mononuclear cells and extracellular vesicles. In dengue virus infection, thrombocytopenia and platelet dysfunction occur. There are likely both common and distinct mechanisms underlying bleeding in different VHFs, as sites of bleeding differ between the viruses. Herein, we discuss the potential mechanisms leading to bleeding during VHF, which include a consumptive coagulopathy, decreased coagulation factor production, thrombocytopenia and platelet dysfunction, and endothelial cell activation and damage, resulting in increased vascular permeability. While a significant body of work exists examining different aspects of the various viral infections that may lead to bleeding, there are still many open questions and areas for investigation. Therefore, more studies are needed to better understand the mechanisms underlying bleeding in VHF caused by different viruses.

29 December 2025 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
MPMegan V. Perkins
Megan V. Perkins
SASierra J. Archibald
Sierra J. Archibald
ASAna Teresa Azevedo Sachetto
Ana Teresa Azevedo Sachetto
NMNigel Mackman
Nigel Mackman
Tissue factor (TF) is a receptor for factor (F)VII/FVIIa and is essential for hemostasis. TF is expressed in a tissue-specific manner, with differing TF levels across tissues. TF expression is increased in a variety of diseases, so accurate measurement of TF protein levels is important. The goal of this study was to evaluate the ability of 4 commercial antibodies to measure TF in various mouse tissues using western blotting. We used the goat anti-mouse TF polyclonal antibody AF3178 (R&D Systems), the rabbit anti-mouse TF monoclonal antibody ab189483 (Abcam), the rabbit anti-mouse TF monoclonal antibody 44861 (Cell Signaling Technology), and the mouse anti-mouse TF monoclonal antibody H9 (Santa Cruz Biotechnology) to measure TF in the mouse pancreatic cancer cell line KPC2 wild-type and KPC2 TF knockout cell lysates, as well as various tissues from wild-type and low TF mice (no mouse TF expression) using western blotting. All 4 antibodies detected TF in KPC2 wild-type cells but not in KPC2 TF knockout cells. All 4 antibodies detected TF in the brain, lung, heart, kidney, and spleen. The relative amounts of TF in these tissues were consistent with the tissue distribution of TF mRNA reported in previous studies. Nonspecific bands were detected in various tissues with the different antibodies. Our study demonstrated that the Abcam and Cell Signaling Technology anti-mouse TF monoclonal antibodies gave the strongest signal for TF in mouse tissues. However, researchers should be aware that all 4 antibodies also detect nonspecific bands in some tissues.